Precision BioSciences
DTIL
130 hedge funds and large institutions have $357M invested in Precision BioSciences in 2021 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 42 reducing their positions, and 18 closing their positions.
70% more call options, than puts
Call options by funds: $2.6M | Put options by funds: $1.53M
17% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 18
14% more capital invested
Capital invested by funds: $313M → $357M (+$44.3M)
2% more funds holding
Funds holding: 128 → 130 (+2)
5% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 42
0.11% less ownership
Funds ownership: 1.77% → 1.67% (-0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.34M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.8M |
| 3 |
JP Morgan Chase
New York
|
+$3.13M |
| 4 |
Morgan Stanley
New York
|
+$2.18M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$2.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$23.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.38M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.13M |
| 4 |
BlackRock
New York
|
-$2.97M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$2.07M |
DTIL Hedge Fund Activity: Q2 2021 in Review
130 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q2 2021, worth a combined $357M — up 14% from $313M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new DTIL positions and 18 closed out — a net gain of 3 holders — while 44 added to existing stakes and 42 trimmed.
The largest buyer was Candriam SCA, opening a new position worth an estimated $6.34M. The largest seller was State Street, cutting an estimated $23.7M.
- 130 institutional investors held Precision BioSciences (DTIL) as of Q2 2021, up from 128 in Q1 2021.
- Funds reported $357M of Precision BioSciences stock for Q2 2021, up 14% quarter-over-quarter.
- 21 funds opened new Precision BioSciences positions in Q2 2021 and 18 closed out, a net change of +3 holders.
- The largest Precision BioSciences buyer in Q2 2021 was Candriam SCA, an estimated $6.34M added.
- The largest Precision BioSciences seller in Q2 2021 was State Street, an estimated $23.7M sold.
Based on aggregated 13F filings for Q2 2021.